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Alzheimer’s disease (AD) is the most common form of dementia in the elderly, and
affects millions of people worldwide. As the number of AD cases continues to increase
in both developed and developing countries, finding therapies that effectively halt or
reverse disease progression constitutes a major research and public health challenge.
Since the identification of the amyloid-β peptide (Aβ) as the major component of the
amyloid plaques that are characteristically found in AD brains, a major effort has aimed
to determine whether and how Aβ leads to memory loss and cognitive impairment.
A large body of evidence accumulated in the past 15 years supports a pivotal role
of soluble Aβ oligomers (AβOs) in synapse failure and neuronal dysfunction in AD.
Nonetheless, a number of basic questions, including the exact molecular composition
of the synaptotoxic oligomers, the identity of the receptor(s) to which they bind, and
the signaling pathways that ultimately lead to synapse failure, remain to be definitively
answered. Here, we discuss recent advances that have illuminated our understanding
of the chemical nature of the toxic species and the deleterious impact they have
on synapses, and have culminated in the proposal of an Aβ oligomer hypothesis for
Alzheimer’s pathogenesis. We also highlight outstanding questions and challenges in AD
research that should be addressed to allow translation of research findings into effective
AD therapies.
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Introduction
Alzheimer’s disease (AD) is a severe neurodegenerative disorder characterized by memory loss
and progressive cognitive disability. It is the most prevalent form of dementia in the elderly,
affecting more than 40 million people worldwide (Alzheimer’s Association, 2015). The number
of AD cases is reportedly increasing and is expected to almost double by 2030 (Brodaty et al.,
2011).
The current scenario is bleak: disease-modifying therapies are still not available, and existing
strategies do not target potential causes of AD but rather downstream events in the disease. AD
is a disease of complex etiology and, despite intense research efforts in the past few decades, no
effective therapeutic approach has translated into clinical application. Meanwhile, costs associated
with patient care and symptomatic therapeutics have escalated, making AD a major public health
challenge in both developed and developing countries.
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 May 2015 | Volume 9 | Article 191
Ferreira et al. AβO sinaptotoxicity in Alzheimer’s disease
Understanding in molecular detail how AD develops
represents a critical step towards determining which molecules
and pathways should be targeted to efficiently halt or reverse
neurological outcomes. AD is primarily a sporadic disorder: age
is the main risk factor (LaFerla and Oddo, 2005) and fewer than
5% of the cases appear associated to familial inheritance (less than
1% linked to APP mutations; Tanzi and Bertram, 2001; Herrup,
2010). Thus, identification of toxins that accumulate with aging
in the AD brain and the aberrant signaling pathways that lead to
synapse dysfunction holds significant potential to pave the way
for successful new therapeutic approaches.
Here, we focus on the discovery of soluble Aβ oligomers
(AβOs) as toxins that accumulate in the AD brain and target
synapses, and how these findings have led to significant advances
in our understanding of mechanisms of memory impairment.
We address the still unresolved issue of what is/are the
receptor(s) to which AβOs bind at synapses, and further discuss
recent evidence indicating that different oligomeric assemblies of
Aβ may act together to orchestrate the complex pathogenesis of
AD. Finally, we offer perspectives on how accumulated evidence
from basic research might translate into clinical applications
in AD.
From Insoluble Amyloid Plaques to Soluble
Aβ Oligomers
Following the initial description of the presence of amyloid
plaques in the brain of a severely demented patient (Alzheimer,
1907; English-translated version in Alzheimer et al., 1995), eight
decades passed before initial clues on their composition emerged.
In 1984, Glenner and Wong isolated a novel peptide derived
from AD-linked cerebrovascular pathology (Glenner and Wong,
1984). One year later, Masters and co-workers found that the
same peptide, termed amyloid-β peptide (Aβ), is the principal
component of amyloid plaque cores isolated from AD brains
(Masters et al., 1985).
Aβ is a 4 kDa peptide (with 40- and 42-amino acid residue
peptides as the predominant species) derived from proteolytic
cleavage of a precursor protein termed amyloid precursor protein
(APP; Kang et al., 1987; De Felice et al., 2004; Gralle and Ferreira,
2007). Aβ monomers readily aggregate in aqueous medium,
giving rise to various types of assemblies including oligomers,
protofibrils and amyloid fibrils. While AβOs are soluble and
may spread throughout the brain, amyloid fibrils are larger
and insoluble, and assemble into amyloid plaques, forming
histological lesions that are characteristic of AD.
The idea that amyloid plaques might account for
neurodegeneration (specifically, nerve cell death) and cognitive
decline in AD became established in the so-called ‘‘amyloid
cascade hypothesis’’, supported by robust in vitro evidence
pointing to a neurotoxic role of Aβ aggregates (e.g., Saitoh
et al., 1989; Kowall et al., 1991; Pike et al., 1993; Lorenzo and
Yankner, 1994), and put forward in an influential review by
Hardy and Higgins (Hardy and Higgins, 1992). The central
feature of that proposal was that deposition of aggregated Aβ
into plaques would lead to neuronal death, ultimately causing
dementia.
Nonetheless, as early as 1991, an intriguing report by
Terry and colleagues (Terry et al., 1991) had demonstrated
that synapse loss, rather than amyloid plaque load, provided
the best pathological correlate of memory decline in AD.
That notion was further supported by other studies that
did not find direct correlation between plaque deposition
and synapse/neuritic loss in postmortem analysis of AD
brains (e.g., Masliah et al., 1990, 1993; Dickson et al., 1995).
Further indicating a disconnect between plaque pathology
and memory impairment, several groups reported that
cognitive deficits in transgenic mouse models of AD appeared
before plaque deposition or detection of insoluble amyloid
aggregates in their brains (e.g., Hsia et al., 1999; Mucke et al.,
2000; Westerman et al., 2002). Those observations puzzled
researchers for years, and those transgenic animals were not
regarded as bona-fide AD models because they exhibited
memory impairment in the absence of plaque deposition.
Nevertheless, we now understand that the build-up of soluble
Aβ species, unknown and undetected at that time, likely
underlies memory impairment in such transgenic mice (see
below).
The apparent controversy on how amyloid-β toxicity
correlated with cognitive decline andmemory impairment in AD
began to be resolved in 1998. In a seminal study,William L. Klein
and colleagues demonstrated that, in addition to the well-known
amyloid fibrils involved in plaque formation, Aβ spontaneously
forms small, soluble oligomeric assemblies they termed Aβ-
derived diffusible ligands (ADDLs). Although oligomeric Aβ
had already been described at that time (Podlisny et al., 1995;
Kuo et al., 1996; Roher et al., 1996), Lambert et al. (1998) first
established that ADDLs could act as neurotoxins in the absence
of amyloid fibrils or larger aggregates. ADDLs were shown to
inhibit LTP and to promote cell death in a Fyn-dependent
mechanism (Lambert et al., 1998). AβOs (more generally referred
to as AβOs) are increased in AD brain extracts (Walsh et al.,
2002; Gong et al., 2003; Kayed et al., 2003; Lacor et al., 2004;
Townsend et al., 2006; Klyubin et al., 2008; Shankar et al.,
2009; Xia et al., 2009) and can be detected using oligomer-
sensitive antibodies (Lambert et al., 2001, 2007; Kayed et al.,
2003; Rasool et al., 2013), but are not detected by conventional
histopathological techniques, such as staining with Thioflavin S
or Congo Red.
Soon after their identification, oligomers were incorporated
into a revised version of the amyloid cascade hypothesis (Klein
et al., 2001; Hardy and Selkoe, 2002; Selkoe, 2002a), which
posited that soluble AβOs, rather than insoluble fibrils or
plaques, would trigger synapse failure and memory impairment.
As a corollary, AD would be a disorder of synapses (Selkoe,
2002b), and neuronal loss would only account for impaired brain
function at final stages of the disease.
The emergence of AβOs as neurotoxins has considerably
modified our understanding of disease mechanisms, not
only in the specific case of Alzheimer’s but also of other
neurodegenerative disorders in which oligomers formed by other
proteins play causal roles (reviewed in Ferreira et al., 2007).
Recently, this notion received support from promising results
of a Phase 1 clinical trial of the high affinity antibody BIIB037
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(Aducanumab), which binds both plaques and soluble oligomers
(Clinical Trial ID # NCT01677572). BIIB037 has now been
pushed into a Phase 3 trial and results are highly anticipated.
In the following sections, we review multiple
synaptotoxic/neurotoxic effects of AβOs, which led to the
proposal of an ‘‘Aβ oligomer hypothesis’’ of AD (Ferreira and
Klein, 2011) in an attempt to better explain how oligomer
accumulation in the brain leads to memory decline and cognitive
dysfunction in AD.
The Quest for AβO Receptors
AβOs appear to interact with a number of postsynaptic proteins
assembled into a putative neuronal receptor complex that may
include ionotropic and metabotropic glutamate receptors, the
cellular prion protein (PrPC), neuroligin, the Wnt receptor
Frizzled and insulin receptors, among other constituents
(reviewed in Krafft and Klein, 2010; Ferreira and Klein, 2011;
Viola and Klein, 2015). Many neurotoxic effects have been
described as resulting from the interaction of AβOs with several
receptors or co-receptors. We here provide a brief description of
the main components of a putative receptor complex assembled
by AβOs.
Glutamate Receptors
Glutamate receptors have been closely implicated in the
neurotoxicity of AβOs (Ferreira and Klein, 2011). Indeed, AβOs
have been reported to interact with AMPA-type and NMDA-
type ionotropic receptors (De Felice et al., 2007; Decker et al.,
2010a; Zhao et al., 2010), as well as with type 5 metabotropic
glutamate receptor (mGluR5; Renner et al., 2010; Um et al.,
2013). AβOs appear to target synaptic sites in close proximity
to AMPA receptors (AMPARs), and downregulation of AMPAR
subunits prevents AβO binding to neurons (Zhao et al., 2010).
We have found that knockdown of NMDA receptors by a viral
vector-mediated antisense approach (Decker et al., 2010a) or
treatment of neurons with an antibody against the extracellular
domain of the constitutive NR1 subunit of NMDA receptors (De
Felice et al., 2007) block binding of AβOs to neuronal surface
membranes. At the same time, however, presence of NMDA
receptors on the neuronal surface is not sufficient for binding
of AβOs to hippocampal neurons (Decker et al., 2010a). These
results suggest that NMDA receptors are an integral component,
likely an organizer of a receptor complex that binds oligomers at
the neuronal surface.
Another protein that has received considerable recent
attention as a putative oligomer receptor is mGluR5 (Renner
et al., 2010; Hamilton et al., 2014; Hu et al., 2014). AβOs
are capable of inducing mGluR5 clustering at the membrane,
a mechanism responsible for increased calcium influx and
neurotoxicity (Renner et al., 2010). Deletion of mGluR5 rescues
memory deficits in APP/PS1 mice (Hamilton et al., 2014).
Notably, both NMDARs and mGluR5 interact closely with PrPC
at the neuronal plasma membrane (Khosravani et al., 2008;
Beraldo et al., 2011; Um et al., 2013), further suggesting that they
may be part of a PrPC-containing oligomer receptor complex (see
below).
Prion Protein
Much attention has also been given to the role of PrPC in
oligomer binding. Since the original report that PrPC binds
AβOs and transduces neurotoxic signals (Laurén et al., 2009),
there has been some controversy as to whether PrPC is indeed
necessary for oligomer binding and/or oligomer-induced brain
dysfunction (Balducci et al., 2010; Kessels et al., 2010; Forloni and
Balducci, 2011; Fluharty et al., 2013). Nonetheless, the possibility
that PrPC is a key component of an oligomer receptor complex
remains attractive. Interestingly, exposure to AβOs recruits
PrPC molecules to the neuronal surface (Caetano et al., 2011),
consistent with functional interaction between oligomers and
PrPC triggering signaling pathways to causememory impairment
(Gimbel et al., 2010; Um et al., 2012, 2013; Peters et al.,
2015). Notably, AβO-induced Fyn activation, as previously
demonstrated by Lambert et al. (1998), requires a receptor
complex containing PrPC and mGluR5 to cause neurotoxicity
and memory impairment (Um et al., 2012, 2013). Furthermore,
it was recently demonstrated that pharmacological inhibition
of Fyn rescued cognitive performance in an AD mouse model
(Kaufman et al., 2015).
Frizzled Receptors
Wnt signaling has been shown to participate in many aspects
of neuronal survival and function (Varela-Nallar and Inestrosa,
2013; Ríos et al., 2014). In the canonical pathway, Wnt
binds to Frizzled receptors to stimulate β-catenin nuclear
translocation and GSK-3β inhibition. We have reported that
AβOs bind to a cysteine-rich domain of Frizzled that is directly
involved inWnt binding, thus impairing neuronal Wnt signaling
(Magdesian et al., 2008) and resulting in altered expression of
Wnt target genes, possibly including some related to synaptic
plasticity mechanisms. Interestingly, Wnt has been found to be
protective against the neurotoxicity of AβOs, reducing caspase-3
activation upon Frizzled-1 overexpression. Consistently, deletion
of Frizzled-1 potentiated AβO effects (Chacón et al., 2008).
Furthermore, activation of Wnt signaling counteracts behavioral
impairments in AD mice (De Ferrari et al., 2003; Toledo
and Inestrosa, 2010; Silva-Alvarez et al., 2013; Vargas et al.,
2014). Thus, it is likely that recruitment of Frizzled to AβO
receptor complexes precludes the activation ofWnt signaling and
facilitates neuronal damage.
Neuroligin
AβOs were reported to interact with the N-terminal tyrosine-rich
domain of neuroligin-1. Moreover, in vitro purified N-terminal
fragment of neuroligin stabilizes Aβ aggregates (Dinamarca et al.,
2011). Intriguingly, neuroligin-1 can be cleaved under conditions
of neuronal hyperexcitability, known to develop in AD (Sanchez
et al., 2012; Vossel et al., 2013), in a process mediated by
NMDARs (Suzuki et al., 2012). This could result in increased free
extracellular N-terminal neuroligin fragments, thus facilitating
AβO nucleation. Binding of AβOs to neuroligin could directly
impact synapses, given that neuroligin associates with several
partner proteins to maintain synapse structure and function.
On the other hand, it was recently shown that amyloid fibrils
suppress neuroligin expression to promote neurodegeneration
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(Bie et al., 2014). A combination of such events is likely to
accelerate synapse damage and bran dysfunction in AD.
Sigma-2/PGRMC1 Receptor
Sigma-2/PGRMC1 is the most recently described putative AβO
receptor, and appears essential for oligomer neurotoxicity (Izzo
et al., 2014a,b). AβOs increase total levels of this receptor in
cultured hippocampal neurons (Izzo et al., 2014a), and both
inhibition and knockdown of Sigma-2/PGRMC1 abolished AβO
binding to synapses. Notably, a small molecule antagonist of
Sigma-2/PGRMC1 receptors reversed AD memory impairment
in the hAPPSwe/Ldn mouse model of AD (Izzo et al., 2014b).
Future studies are warranted to understand how this protein
might participate in the oligomer receptor complex, and which
downstream signaling mechanisms promote neurotoxicity.
Other Protein Receptors
In addition to the ones listed above, several other proteins
have been reported to interact with AβOs. These include
EphB2, p75 neurotrophin receptor (p75NTR), α7-nicotinic
receptor, adrenergic receptors, receptor for advanced glycation
end-products (RAGE), calcium channels, and less known
components, such as LilRb2, formyl-peptideR2 and FcγRIIb
(see Patel and Jhamandas, 2012; Viola and Klein, 2015, for
reviews). Sortilin, in association with p75NTR, has also emerged
as a candidate AβO binding protein (Takamura et al., 2012).
Recently, AβOs have been reported to target ephrin A4 receptors
to mediate synapse and cognitive dysfunction in AD mouse
models (Fu et al., 2014; Overk and Masliah, 2014; Vargas et al.,
2014).
Non-Protein Receptors
Initial evidence provided by Lambert et al. (1998) indicated
that AβO binding is trypsin-sensitive, suggesting that protein
receptors are required for AβO interactions. Nevertheless, other
types of molecules have been proposed to act as oligomer ligands.
The ganglioside GM1 is a non-protein AβO ligand that has
attracted considerable interest in recent years. AβOs target GM1-
containing regions and lipid rafts (Hong et al., 2014), and
bind directly to GM1 to promote neuronal damage (Williams
et al., 2011; Calamai and Pavone, 2013). Furthermore, GM1-
rich membrane domains are preferential sites for Aβ aggregation
(Ogawa et al., 2011; Yamamoto et al., 2012, 2014), suggesting that
GM1 could play an important role in the formation of seeds for
Aβ oligomerization.
Some evidence also suggests that AβOs can bind directly to
lipid membranes (Canale et al., 2013; Yates et al., 2013; Lee
et al., 2014a), occasionally forming toxic pores (Arispe et al.,
1993, 1996; Tofoleanu and Buchete, 2012; Zhang et al., 2012;
Di Scala et al., 2014; Lee et al., 2014a), or serve as ligands to
non-protein molecules within the plasma membrane, raising
the possibility that direct neurotoxicity could be initiated by
membrane interactions of sticky AβOs. A problem with this
hypothesis, however, is that it fails to explain how intricate
and specific cell-signaling effects could result from non-specific
interactions of AβOs with the lipid bilayer at the plasma
membrane.
Direct and Indirect Interactions
Studies published during the past few years have resulted in
a list of more than 15 proteins, some of which are reviewed
above, that could act as oligomer receptors at the neuronal
plasma membrane (Viola and Klein, 2015). Nonetheless, the
nature of such interactions remains elusive in most cases. Few
molecules, such as PrPC, neuroligin and Frizzled, have been
shown to directly interact with AβOs, but the identity of the
putative X receptor that mediates initial binding of oligomers is
still unknown. Nevertheless, knockdown or depletion of several
candidate receptors significantly reduce AβO binding to neurons
or toxicity. This suggests that a multi-protein receptor complex is
assembled by oligomers and mediates toxic signal transduction.
It is of interest that PrPC, known to physically bind AβOs,
appears to function as a signaling platform at the neuronal
plasma membrane, interacting with numerous partners (Linden
et al., 2008). Thus, PrPC may be well suited to act as an organizer
of a multi-protein receptor complex responsible for the binding
and transduction of the multiple neurotoxic effects of AβOs.
Initial interaction between AβOs and their immediate
partners could be followed by recruitment of additional
components to stabilize AβO binding. Thus, any single member
of such a receptor complex would be required but not sufficient
to maintain bound AβOs, as is the case for NMDAR (Decker
et al., 2010a). Still, given the heterogeneity of oligomers
populations, it is possible that oligomers of different sizes bind
to different components within the receptor complex, increasing
the complexity of signaling mechanisms.
AβOs as Synaptotoxins in AD
Soluble Aβ (McLean et al., 1999) and AβOs accumulate in the
brains and CSF of AD patients (Gong et al., 2003; Kayed et al.,
2003; Lacor et al., 2004; Georganopoulou et al., 2005; Haes
et al., 2005; Anker et al., 2009; Herskovits et al., 2013; Viola
et al., 2015). Interestingly, oligomers are found at elevated levels
and in association with synapses in the brains of demented
AD individuals (Koffie et al., 2009; Bjorklund et al., 2012;
Perez-Nievas et al., 2013), but they have not been detected at
synapses in the brains of individuals who lacked pre-mortem
cognitive impairment but whose brains presented typical AD
neuropathology (Bjorklund et al., 2012). This suggests that the
synaptic attack by AβOs could constitute the event leading to
memory/cognitive dysfunction in AD. Immunofluorescence co-
localization studies have revealed that AβOs target excitatory
synapses (Lacor et al., 2004; Takahashi et al., 2004; Kokubo
et al., 2005) and promote modifications in synapse structure
and composition that disrupt synaptic function (e.g., Lacor
et al., 2007; Shankar et al., 2007; Figueiredo et al., 2013).
Although most current knowledge on the synaptic impact
of AβOs comes from studies in cell culture or in rodent
brains, these findings were recently corroborated in a novel
non-human primate model of AD (Forny-Germano et al.,
2014).
Although some evidence indicates that, at very low
(picomolar) concentrations, AβOs may be important for
proper synapse function (Puzzo et al., 2008, 2011; Garcia-Osta
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and Alberini, 2009; Lee et al., 2014b; Ricciarelli et al., 2014),
increased levels of AβOs impair synaptic plasticity by inhibiting
LTP (e.g., Lambert et al., 1998; Walsh et al., 2002; Klyubin et al.,
2005, 2012; Gong et al., 2006; Hu et al., 2008; Jürgensen et al.,
2011; An et al., 2013) and facilitating LTD (Wang et al., 2002;
Li et al., 2009; Ma et al., 2013; Hu et al., 2014). Importantly,
oligomers instigate memory impairment in rodents (Cleary et al.,
2005; Lesné et al., 2006; Poling et al., 2008; Shankar et al., 2008;
Figueiredo et al., 2013; Ledo et al., 2013; Lourenco et al., 2013),
and blocking de novo AβO production acutely reverses synapse
loss and memory impairment in APP transgenic mice in the
absence of plaque load changes (Fowler et al., 2014).
Many studies have provided evidence (largely
from immunofluorescence co-localization and/or co-
immunoprecipitation experiments) supporting the notion
that AβOs bind to excitatory synapses. However, recent studies
have provided evidence that oligomers also bind to axons, albeit
less robustly than to dendrites (Baleriola et al., 2014; Gan and
Silverman, 2015), and that axonal bindingmay be, at least in part,
responsible for the inhibition of fast axonal transport induced
by AβOs (Decker et al., 2010b; Bomfim et al., 2012; Ramser
et al., 2013). The specificity of synaptic targeting by AβOs thus
deserves further examination.
Once bound to neurons, oligomers trigger multiple aberrant
signaling pathways, including abnormal calcium signaling,
oxidative stress, tau hyperphosphorylation, removal of plasticity-
related receptors (e.g., AMPA and NMDA receptors) from
synapses, impaired axonal transport, increased glutamate release
from pre-synaptic terminals and elevated D-serine levels,
endoplasmic reticulum (ER) stress and inflammation (Roselli
et al., 2005; Rowan et al., 2005; Snyder et al., 2005; Hsieh
et al., 2006; De Felice et al., 2007, 2008; Shankar et al., 2008;
Decker et al., 2010a,b; Kurup et al., 2010; Saraiva et al., 2010;
Wu et al., 2010; Brito-Moreira et al., 2011; Jürgensen et al.,
2011; Miñano-Molina et al., 2011; Paula-Lima et al., 2011; Zhang
et al., 2011; Bomfim et al., 2012; Yoon et al., 2012; Lourenco
et al., 2013; Ma et al., 2013; Ramser et al., 2013; Madeira et al.,
2015).
Tau hyperphosphorylation and development of
neurofibrillary tangles (NFTs) are hallmarks of human
AD pathology, and several studies have tried to unveil a
potential relationship between amyloid and tau pathologies.
Following the initial demonstration that AβOs induce tau
hyperphosphorylation in cultured neurons (De Felice et al.,
2008), other studies have extended those findings (Ma et al., 2009;
Jin et al., 2011), and showed that tau is hyperphosphorylated
in mice with increased AβO levels (Chabrier et al., 2012). The
specificity of these events is supported by the fact that anti-Aβ
antibodies block aberrant tau phosphorylation in vitro (De Felice
et al., 2008; Jin et al., 2011) and in vivo (Serrano-Pozo et al.,
2010). Moreover, tau hyperphosphorylation and NFT formation
were recently demonstrated in a novel monkey model of AD
generated by intracereboventricular (i.c.v.) injection of AβOs
in cynomolgus monkeys (Forny-Germano et al., 2014). Recent
evidence further suggests that amyloid pathology accelerates tau
hyperphosphorylation and propagation in vivo (Pooler et al.,
2015).
Tau can be phosphorylated by several kinases that are
overactive in AD brains (e.g., GSK-3β, Cdk5, Cdc2, PKR, JNK
and other MAPKs; reviewed by Mandelkow and Mandelkow,
2012). Significant evidence suggests that AβO-mediated tau
phosphorylation leads to cytoskeleton disruption and synaptic
loss (Zempel et al., 2010, 2013; Zempel and Mandelkow, 2012).
Zempel and collaborators have shown that AβOs induce tau mis-
sorting, a phenomenon in which axonal taumoves to dendrites in
hyperphosphorylated form, disrupting cytoskeletal organization
and axonal transport (Zempel et al., 2010), ultimately instigating
neuronal collapse. In accord with this notion, AβOs were shown
to impair activity-dependent tau re-localization in neurons
(Frandemiche et al., 2014).
Tau pathology has further been shown to cause brain
oxidative and ER stress in animal models of AD (Dias-
Santagata et al., 2007; Abisambra et al., 2013; Frost et al., 2014)
and, of clinical relevance, Aβ-linked cortical volume loss only
develops in the presence of p-tau, further connecting amyloid
to tau pathology (Desikan et al., 2011). Deletion of tau was
further shown to protect hippocampal cultures from the toxicity
of fibrillar Aβ and APP23 mice from developing cognitive
impairment mediated by Fyn (Ittner et al., 2010).
Successive failures of anti-amyloid therapeutics in promoting
cognitive benefits in AD patients has raised the possibility that
tau might be a better target for therapeutic development, given
its involvement in disease mechanisms. Nonetheless, despite the
toxic effects aberrant tau may cause, considerable evidence now
indicates that AβOs act upstream of tau to promote neuronal
dysfunction. In fact, some aspects of toxicity, such as defective
BDNF axonal transport, are not necessarily dependent on tau
(Ramser et al., 2013; Takach et al., 2015). Thus, specific targeting
of AβOs could be the key for developing effective approaches to
prevent both tau-dependent and tau-independent defects in AD.
Of considerable interest are findings that AβOs impair
neuronal insulin signaling (Townsend et al., 2007; Zhao et al.,
2008; De Felice et al., 2009; Bomfim et al., 2012), providing an
explanation at the molecular/cellular level for the connection
between AD and diabetes revealed by clinical/epidemiological
studies (reviewed in De Felice, 2013). Insulin receptors are widely
distributed in the brain (Zhao and Alkon, 2001; Zhao et al.,
2004). In addition to its regulatory actions in energy metabolism,
insulin has been found to play important roles in synaptic
plasticity (Chiu et al., 2008), learning and memory (reviewed in
Fernandez and Torres-Alemán, 2012). Following the discovery
that AβOs trigger removal of insulin receptors from neuronal
plasma membranes (Zhao et al., 2008; De Felice et al., 2009), we
have shown that oligomers instigate activation of neuronal stress
kinases, including c-Jun N-terminal kinase (JNK), IκB kinase
(IKK), and double-stranded RNA-dependent kinase (PKR),
resulting in phosphorylation of the insulin receptor substrate 1
(IRS-1) at inhibitory serine residues, and blocking downstream
signaling in the insulin pathway (Bomfim et al., 2012). This
mechanism is analogous to what takes place in peripheral tissue,
leading to insulin resistance in type II diabetes (Hotamisligil
et al., 1996; Gregor and Hotamisligil, 2011). Combined removal
of insulin receptors from the plasma membrane and serine
phosphorylation of IRS-1 effectively blocks neuronal insulin
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signaling (as verified in AD brain tissue; Talbot et al., 2012), thus
impeding plasticity-related actions of insulin at synapses.
Additional AβO-triggered mechanisms of synaptic
dysfunction have been elucidated in the past few years. Of
particular interest, elevated eIF2α phosphorylation (eIF2α-P)
was recently correlated to synapse loss induced by AβOs
(Lourenco et al., 2013), consistent with the finding that eIF2α
kinases are overactive in brain areas responsible for memory
processes in AD (Chang et al., 2002; Hoozemans et al., 2005;
Yoon et al., 2012; Ma et al., 2013) and with the known role of
eIF2α-P in attenuating global protein translation (Buffington
et al., 2014). Importantly, suppression or inhibition of eIF2α
kinases improves learning and memory in a physiological
context (Costa-Mattioli et al., 2005, 2007; Zhu et al., 2011;
Di Prisco et al., 2014) and alleviates memory deficits in AD
models (Lourenco et al., 2013; Ma et al., 2013). Synapse damage
and loss in AD might further be mediated by a mechanism
involving ER stress and activation of the unfolded protein
response (UPR), which comprises eIF2α-P as a key player. In
fact, elevated levels of UPR markers are found in AD models
(Lourenco et al., 2013; Ma et al., 2013), as well as in postmortem
AD brains (Chang et al., 2002; Hoozemans et al., 2005, 2009;
Chafekar et al., 2007; Yoon et al., 2012). Aberrant activation
of the UPR and, in particular, eIF2α-P appears dependent
on elevated TNF-α levels and TNFR1 activity, pointing to a
central role of neuroinflammation in synapse loss and memory
impairment in AD models (Lourenco et al., 2013). Blocking
TNFR1 signaling or alleviating brain ER stress through the
use of chemical chaperones abrogate AβO-induced cognitive
impairment (Lourenco et al., 2013), in accordance with findings
in AD transgenic models (He et al., 2007; McAlpine et al., 2009;
Ricobaraza et al., 2009, 2012).
Differential Impact of Low- and
High-Molecular Weight AβOs on Synapses
As noted above, AβOs trigger multiple neurotoxic/synaptotoxic
mechanisms in vitro and in vivo, resulting in impaired cognition.
Most of the current knowledge on the neuronal impact of AβOs
comes from studies using cell-derived or synthetic oligomer
preparations comprising a mixture of species ranging from
low-n oligomers (dimers, trimers, tetramers) to higher-order
assemblies typically ranging in MW from 50 to 150 kDa.
The complete molecular pathway that leads to Aβ aggregation
in its multiple oligomeric forms is still unclear. Although still
controversial, significant evidence points to the roles of seed
species, including Aβ dimers, trimers and Aβ*56, in the build
up of amyloid in the brain (Bitan et al., 2003; Hellstrand et al.,
2010; O’Nuallain et al., 2010; Garai and Frieden, 2013; Tsigelny
et al., 2014). Aβ monomers rapidly assemble into oligomers that
might or not consecutively turn into higher-order aggregates
(Rangachari et al., 2007; Velasco et al., 2012), and a stepwise
aggregation process has been proposed to generate AβOs in the
AD brain (Velasco et al., 2012). Whatever the precise pathway of
aggregation of Aβ, highmolecular weight oligomers are increased
in the CSF of AD patients (Fukumoto et al., 2010) and in AD
brain (Gong et al., 2003). In APP/PS1 mice, both low and high
molecular weight oligomers are increased in the CSF (Takeda
et al., 2013).
Given their molecular heterogeneity, it is possible that
different oligomeric species trigger diverse effects in the brain by
recruiting distinct signaling mechanisms. This is in line with the
complex spectrum of molecular/behavioral outcomes seen in a
multifaceted disorder such as AD. Indeed, specific Aβ assemblies
(e.g., dimers, trimers and Aβ*56) have been reported to mediate
distinct pathological effects in the diseased brain (e.g., Lesné et al.,
2006, 2013; Reed et al., 2011).
Recently, we reported that low molecular weight (LMW;
dimers-tetramers) and high molecular weight (HMW; ranging
from ∼50 to ∼150 kDa) AβOs have different impacts on
synapses, despite the fact that both LMW and HMW oligomers
cause memory deficits in mice (Figueiredo et al., 2013).
While LMW oligomers alter synaptic composition (revealed by
decreased synaptophysin immunoreactivity), HMW oligomers
induced neuronal oxidative stress via activation of NMDA
receptors. Notably, mice i.c.v. injected with HMW oligomers
had recovered from memory impairment 14 days post-injection,
while memory damage persisted in mice injected with LMW
oligomers (Figueiredo et al., 2013). It is, thus, likely that
persistent memory impairment triggered by LMW oligomers
results from synapse loss, while the reversible memory loss
induced by HMW oligomers may result from aberrant activation
of NMDARs, which could be blocked by memantine (Figueiredo
et al., 2013). The differential impact on synapses is further
supported by a recent report showing that low-n and high-n
oligomers have differential binding affinities for neurons, with
a population that ranges from decamers to hexadecamers
exhibiting preferential synapse targeting (Velasco et al., 2012).
HMW species have been recently found to significantly interact
with PrPC in AD brains (Dohler et al., 2014), suggesting that
PrPC might be important for transducing signals of defined AβO
assemblies.
Low-molecular weight oligomers (SDS-stable dimers, trimers
and tetramers) were shown to cause synapse loss (Shankar et al.,
2007) and acutely impair synaptic plasticity (Chen and Glabe,
2006), with a particularly toxic role for trimers (Townsend
et al., 2006). LMW oligomers were also reported to cause tau
phosphorylation, cytoskeleton destabilization and cell loss in vivo
(Davis et al., 2011; Brouillette et al., 2012).
Elevated Aβ dimers are detected in an age-dependent manner
in AD brain (Lesné et al., 2013) and in the brains of J20
APP transgenic mice (Shankar et al., 2009). Dimers isolated
from AD brain or CSF impair synapse homeostasis in vivo
(Klyubin et al., 2008; Shankar et al., 2008) and their neutralization
by monoclonal antibodies corrects synaptic plasticity defects
(Klyubin et al., 2008; O’Nuallain et al., 2011). Interestingly,
levels of Aβ dimers are increased in AD patients independently
of disease progression, suggesting that once a certain level
of dimers is attained in the brain, further accumulation is
not necessary for disease progression (McDonald et al., 2012).
Trimers, on the other hand, correlate with increased in vitro
neurotoxicity (Hung et al., 2008) and are thought to act as seeds
for generation of high-molecular weight oligomers (Matsumura
et al., 2011).
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Nonetheless, the actions of dimers/trimers on synapses and
cognition remain somewhat controversial as recent reports
found that preparations of Aβ dimers did not impact LTP in
hippocampal slices (O’Malley et al., 2014) and transgenic brain-
extracted trimers did not impact memory even when injected
at high concentrations in rats (Reed et al., 2011), findings that
are in harmony with in vivo evidence from Lesné et al. (2006).
Still, the possibility remains that Aβ dimers/trimers are converted
into more toxic species in the presence of additional factors
and biophysical conditions that are specific to aged human
brains.
Additional low-n species, such as tetramers, have also been
proposed to play a distinct role in AD etiology (Bernstein et al.,
2009). In a clinical study, Aβ pentamers and decamers were
found to correlate with alterations in the cholinergic system,
a prominent feature of AD (Bao et al., 2012). Notably, a very
recent study has indicated that HMW oligomers, but not LMW
oligomers, accumulate in forebrain cholinergic regions in AD,
consistent with the deleterious role of AβOs on cholinergic
neurotransmission (Baker-Nigh et al., 2015).
Despite our current knowledge of a myriad of detrimental
actions of AβOs in neurons, most cellular/synaptic effects of
AβOs are still orphan in terms of the identity of the specific
oligomeric assemblies involved. In part, and as recently pointed
out (Benilova et al., 2012), this is due to the heterogeneity
of oligomer preparations used in different studies, which
depends on factors including source of the peptide (i.e.,
synthetic vs. ‘‘naturally secreted’’ by cell lines transfected
with human APP, or brain-extracted oligomers), presence of
chemical/post-translational modifications in the peptide (e.g.,
pyroglutamylation, methione oxidation, tyrosine cross-linking),
the specific protocol used to prepare oligomers, conditions of
storage and aging of oligomer preparations, etc. Intriguingly,
for example, recombinant Aβ42 was reported to aggregate faster
and to be more neurotoxic than its synthetic version (Finder
et al., 2010), and different assembles from synthetic or cell-
derived oligomers were found to vary in terms of cognitive
outcomes in rats (Reed et al., 2011). This exemplifies some of
the complexities involved in comparing results from different
groups and using different experimental approaches, and has
led to considerable controversy and conflict in the literature.
Progress in this area would greatly benefit from identification
of the specific assemblies (minimally, in terms of low vs. high
molecular weight oligomers) involved in specific effects of AβOs
at synapses.
AβOs and their Interactions with Glial Cells
Despite being widely considered neurotoxins that attack synapses
with high affinity, evidence has now accumulated that AβOs also
elicit responses from glial cells, namely astrocytes and microglia.
Indeed, it is plausible that glial responses to AβOs actively
participate in neurotoxicity and brain dysfunction. Still, whether
the same receptor composition as in neurons is required for AβO
binding to glial cells remain unknown.
Astrocytes are known to internalize AβOs (Nielsen et al.,
2010), and a recent report suggested that even low concentrations
of AβOs induce calcium influx and generation of reactive oxygen
species (ROS) in astrocytes, in a mechanism that could even
be triggered by a single oligomer particle (Narayan et al.,
2014). Through ERK signaling, AβOs were also shown to
impair astrocytic metabolism (Tarczyluk et al., 2015) and insulin
signaling (Zhang et al., 2015), likely contributing to the observed
glial reactivity upon exposure to AβOs (Ledo et al., 2013).
Impaired insulin signaling and increased astrogliosis may further
facilitate the production of pro-inflammatory cytokines in the
brain, as suggested by several reports (Carrero et al., 2012; Ledo
et al., 2013; Lourenco et al., 2013). Additional studies are required
to further elucidate how AβOs interact with astrocytes, likely
disturbing their physiology and propagating neurotoxic signals
in the brain.
AβOs also target microglia to promote TNF-α and IL-1β
release (Ledo et al., 2013). TNF-α, in turn, stimulates stress kinase
activity in neurons, resulting in impaired insulin signaling and
cognition in mice (Bomfim et al., 2012; Lourenco et al., 2013).
Cytokine profiling in AD brains suggests that microglial cells
exhibit a phenotype often referred to asM1-like, characterized by
augmented expression of pro-inflammatory cytokines, including
IL-1β and TNF-α (Saijo and Glass, 2011).
Still, it is not clear whether pro-inflammatory responses are
a result of direct or indirect effects of oligomers on microglia.
A number of reports indicate that microglial receptors such
as CD36, RAGE, scavenger receptor B-1 (SCARB-1), scavenger
receptor A1 (SCARA-1) and TLRs 2 and 4, could directly
mediate AβO actions (reviewed by Saijo and Glass, 2011).
On the other hand, AβO neurotoxicity and activation of
aberrant signaling pathways in neurons may result in secretion
of alarmin-like molecules to induce microglial activation.
Indeed, a mechanism of this type has been described involving
CX3CR1, a chemokine receptor essential for neuron-microglia
communication (Fuhrmann et al., 2010).
A complete picture of the contributions of each group of
cytokines and chemokines to AβO toxicity is still not available.
For example, knock out of interleukin-10 (IL-10), an anti-
inflammatory cytokine, ameliorated cognitive impairment in
APP/PS1 mice, consistent with enhanced IL-10 signaling in
AD brains (Guillot-Sestier et al., 2015). Administration of IL-
10 in APP/PS1 mice reduced Aβ phagocytosis, contrary to
observations in IL-10-depleted animals (Guillot-Sestier et al.,
2015). Suppression of interleukin receptor-associated kinase 4
(IRAK4), a downstream effector of TLR activity, resulted in
improved clearance and reduced Aβ levels in APP/PS1 mice
(Cameron et al., 2012). Similarly, overexpression of interleukin-
1β, a pro-inflammatory cytokine, reduced amyloid plaque
burden in 3 × Tg mice, although tau pathology was worsened
(Ghosh et al., 2013).
Upon activation, microglia act as potent phagocytic cells,
and this may be important as a defense mechanism to prevent
early Aβ deposition. However, significant accumulation of AβOs
appears to impair phagocytic activity of microglia. Stimulation
of the PPARy/RXRa heterodimer by selective agonists intensifies
Aβ phagocytosis by microglial cells and improves memory
performance in APP/PS1 mice (Yamanaka et al., 2012). This
appears to be mediated by CD36, a molecule that has reduced
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expression in APP/PS1 mice, in a mechanism that could be
mediated by TNF-α (Hickman et al., 2008).
In conclusion, AβOs impact astrocytic and microglial
physiology, eliciting toxic pro-inflammatory responses,
including TNF-α release, contributing to brain damage in
AD. In addition, it is possible that exposure to increased
AβO levels leads to impairments in mechanisms essential for
proper brain function, such as neuromodulator release and
phagocytosis. Glial loss-of-function instigated by AβOs could
impact neurotransmission and synapse homeostasis, a possibility
supported by recent reports that glial gene expression is essential
for memory and may be disrupted in AD (Matsuno et al., 2015;
Sekar et al., 2015). Thus, glial-mediated effects initiated by AβOs
in the brain may occur by increased release of toxic molecules,
impairment of essential glial functions in neuromodulation,
or both.
Current Challenges in AD Research
Several questions pertaining to the mechanisms of AD pathology
have been resolved after three decades of research centered on
the Aβ peptide. Yet, many major questions still demand answers,
particularly regarding the specific synaptotoxic/neurotoxic
outcomes of the accumulation of low and high molecular weight
AβOs in the AD brain. Further, the precise mechanisms by
which oligomers trigger neurotoxicity are not fully understood
(Benilova and De Strooper, 2011). One possibility is that AβOs
bind to a multi-protein receptor complex at the neuronal
surface, and this triggers parallel aberrant activation of several
signaling pathways that result in synapse failure and neuronal
damage (Krafft and Klein, 2010; Ferreira and Klein, 2011).
Another possibility is that different-sized oligomers bind to
different receptors, triggering selective neurotoxic pathways.
In this regard, we recently obtained evidence that high and
low molecular weight oligomers do not compete for the
same receptor at neuronal surfaces (Achurra and Ferreira,
unpublished data). It may well be, therefore, that the neuronal
impact of low molecular weight oligomers (which specifically
results in persistent structural damage to synapses revealed by
synaptophysin loss; Figueiredo et al., 2013) differs substantially in
terms of the receptors and activated pathways from the impact of
high molecular weight oligomers, which appears to be centrally
mediated by NMDARs and can be blocked by the NMDAR
channel blocker memantine (Figueiredo et al., 2013).
Another major gap in our current knowledge comprises
the interaction of oligomers with glial cells (notably, astrocytes
and microglia), how such interaction may lead to potentially
damaging aberrant activation of glial cells, and the potential
role of glial cells in oligomer clearance. In particular, nothing is
known about the potentially different interactions of LMW and
HMW oligomers with glial cells.
Lastly, we feel that major efforts should be directed at
generating improved AD models. Most of the currently available
animal models are based on introduction of familial AD-linked
mutations in rodents, resulting in abnormally elevated Aβ levels
and deposition, and AD-like pathology. While such transgenic
models have revealedmany important aspects of ADprogression,
they can at best be considered models for familial (early onset)
cases of AD, which represent nomore than 5% of the total disease
burden (LaFerla and Oddo, 2005). Moreover, as previously
pointed out (Selkoe, 2011), transgenic mouse models of AD
do not recapitulate the full spectrum of AD pathology. For
example, transgenic mouse models of AD lack the NFTs that
are a hallmark of human pathology, and induction of tangle
formation in mice depends on expression of a mutant form of
tau that is not found in AD patients (LaFerla and Green, 2012).
Most transgenic mouse models also fail to exhibit neuronal
death as observed in later states of AD. It is noteworthy that a
recently developed AD rat model engineered to express mutant
human APP and PS1 genes was reported to develop cognitive
impairment accompanied by AβOproduction, tau pathology and
neuronal loss (Cohen et al., 2013), and a mouse model developed
by LaFerla and co-workers expressing Arctic APP at low levels
presented enhanced AβO formation and wild-type tau pathology
(Chabrier et al., 2012).
Also noteworthy is that APP transgenic mice express different
Aβ assemblies (from monomers to plaques), making it difficult
to assign specific pathogenic roles and mechanisms to each
type of Aβ aggregate. An attempt to overcome this hurdle
was the development of a mouse model for AD that markedly
accumulates AβOs and exhibits synapse and memory loss in
the absence of amyloid fibrils and plaque deposition (Tomiyama
et al., 2010). Similar cognitive impairment was found in another
transgenic model at pre-plaque ages (Ferretti et al., 2011).
The inability to recapitulate cardinal features of the
neuropathology of AD, on top of the essential differences
between rodent and human brains in terms of the neural circuitry
and architecture, may explain why a large number of therapeutic
approaches that were validated in transgenic mouse models of
AD have disappointingly failed in human trials.
Recent approaches have been undertaken to develop
alternative experimental models that might be relevant to
sporadic AD and to human pathology. We have shown that
human adult cortical tissue slices can be maintained in culture
for several days, allowing investigation of the effects of AβOs
in ex-vivo human brain tissue (Sebollela et al., 2012). This
approach has allowed an initial investigation of oligomer-
induced changes in gene expression in human brain tissue, and,
among other findings, showed that synaptophysin is markedly
down-regulated, at both mRNA and protein levels, in human
brain tissue exposed to AβOs (Sebollela et al., 2012). Clearly,
access to surgical human brain tissue represents a bottleneck for
wider dissemination of this experimental model. Nonetheless,
the relevance of results obtained in intact human neural tissue
should not be underestimated in considering the translational
potential of this model for development of novel therapeutic
approaches in AD.
In terms of in vivo modeling of sporadic AD, two recent
initiatives are worth mentioning. First, i.c.v. injection of AβOs
in mice triggers aberrant signaling pathways (Bomfim et al.,
2012; Lourenco et al., 2013) that culminate with memory loss
and behavioral alterations that recapitulate clinical observations
in AD patients (Figueiredo et al., 2013; Ledo et al., 2013;
Lourenco et al., 2013). The relative ease of implementation and
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FIGURE 1 | Synapse under siege. A simplified scheme illustrating some of
the mechanisms by which AβOs (AβOs; represented as red asterisks) impact
synapse plasticity and function. At the pre-synaptic terminal, AβOs inhibit
microtubule-based fast axonal transport (FAT) in a tau-independent manner
(Decker et al., 2010b; Ramser et al., 2013; Gan and Silverman, 2015; Takach
et al., 2015), resulting in reduced or interrupted transport of various cargoes,
including brain-derived neurotrophic factor (BDNF), to synapses. FAT inhibition
may involve physical or functional interaction of AβOs with axonal voltage-gated
calcium channels (VGCC), calcium influx into the axon and activation of
calcineurin (CaN). Deregulated calcium levels also triggers increased
pre-synaptic glutamate release (Brito-Moreira et al., 2011). Release of the
NMDA receptor (NMDAR) co-agonist, D-serine, is also increased in neurons
exposed to AβOs (Brito-Moreira et al., 2011; Madeira et al., 2015), resulting in
elevated basal excitatory tonus. At the dendritic spine, AβOs aberrantly activate
NMDARs, triggering increased calcium influx and increased production of
reactive oxygen species (ROS; De Felice et al., 2007; Decker et al., 2010a;
Saraiva et al., 2010; Paula-Lima et al., 2011), likely mediated by mitochondrial
dysfunction. NMDAR-mediated calcium influx causes ryanodyne
receptor-mediated calcium release from endoplasmic reticulum (ER) stores
(Paula-Lima et al., 2011). Elevated calcium levels at the spine activate CaN to
dephosphorylate NMDARs and AMPARs at specific phosphoepitopes, causing
their removal from synapses and internalization (Snyder et al., 2005; Hsieh
et al., 2006; Jürgensen et al., 2011). CaN activation has also been implicated in
Aβ-induced spine loss (Wu et al., 2010; not represented in the scheme for
simplicity). Calcium-dependent activation of calcium/calmodulin-dependent
kinase II (CaMKII) and casein kinase II (CKII) also appears to mediate removal of
NMDARs from synapses (De Felice et al., 2009; not represented in the current
scheme). AβOs block insulin signaling by instigating removal of insulin
receptors (IRs) from the neuronal plasma membrane (De Felice et al., 2009;
not represented here), inhibiting IR autophosphorylation (Zhao et al., 2008; not
represented), and by inhibiting IR-mediated tyrosine phosphorylation of the
insulin receptor substrate-1 (IRS-1; Bomfim et al., 2012; not represented).
AβOs instigate brain microgliosis and increased microglial production/secretion
of TNF-α (Ledo et al., 2013; unpublished results). Aberrant TNF-α signaling
activates cell stress kinases (c-Jun N-terminal kinase, JNK; IκB kinase, IKK;
double-stranded DNA-dependent protein kinase, PKR; Bomfim et al., 2012;
Lourenco et al., 2013), resulting in serine phosphorylation and further inhibition
of IRS-1. PKR also phosphorylates eukaryotic initiation factor 2 α (eIF2α;
Lourenco et al., 2013). eIF2α is further phosphorylated by PKR-related ER
resident kinase (PERK), a kinase that executes one of the three branches of the
unfolded protein response (UPR) that is activated by ER stress in neurons
exposed to AβOs (Lourenco et al., 2013; Ma et al., 2013). Insulin signaling
inhibition and eIF2α-P lead to blockade of protein synthesis, essential for
synaptic plasticity (Buffington et al., 2014). Additional mechanisms (not
included here) thought to further contribute to synapse failure include
deregulation of the actin cytoskeleton at spines (Lacor et al., 2004; Davis et al.,
2011), loss of pre- and post-synaptic proteins (e.g., synaptophysin, PSD-95;
Roselli et al., 2005; Sebollela et al., 2012; Figueiredo et al., 2013), Fyn
kinase-mediated surface removal of NMDARs and spine loss (Um et al., 2012),
among others.
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robustness of this approach make it an attractive alternative for
pathway elucidation as well as for screening of novel treatments
or preventative schemes. It should be kept in mind, however,
that this represents an acute model, as neuropathology and
cognitive deficits are detected between one day and a few weeks
following a single i.c.v. injection of AβOs, much faster than the
course of several months or years for disease progression in
transgenic mice or humans, respectively. It is possible, therefore,
that the acute impact of AβOs in mice brains triggers signaling
pathways that might not play significant roles in the chronic
nature of human disease. Moreover, mechanistic studies in
rodents might not fully recapitulate human disease, as rodents
do not spontaneously develop AD features such as Aβ deposition
and accelerated cognitive decline. Therefore, the creation of
novel animal models that better approximate human AD seems
warranted.
Development of a novel monkey model of AD was recently
reported (Forny-Germano et al., 2014). I.c.v. infusion of
AβOs in cynomolgus monkeys triggered brain pathology that
was quite reminiscent of neuropathological alterations that
are characteristic of AD, including tau hyperphosphorylation,
formation of neurofibrillary inclusions, and synapse loss. The
similarity in pathological features triggered by oligomers and
the overall close proximity between macaque and human brains
suggests that this novel model may be very relevant for studies
aimed to understand in greater detail the mechanisms of
pathogenesis instigated by AβOs, and to improve translation
of experimental results into therapeutic approaches. Such
therapeutic interventions could be useful not only in AD but
also, as recently proposed (Morrison and Baxter, 2014), to
maintain synapse health in age-related cognitive impairment and
to prevent the onset of dementia in the elderly.
Finally, induced pluripotent stem cells (iPSCs) derived from
AD patient fibroblasts (Yagi et al., 2011; Israel et al., 2012; Kondo
et al., 2013) have been generated in the past 4 years. AD-derived
cells present increased tau phosphorylation (Israel et al., 2012)
and Aβ oligomer accumulation (Kondo et al., 2013), and similar
findings were described in a 3D culture of neural stem cells
derived from familial AD cases (Choi et al., 2014). Generation
of sporadic AD-derived iPSCs is of special interest as it might
provide insight into how non-familial AD cases initiate and
develop. As technology for iPSC generation develops and costs
are reduced, it is anticipated that such cells will become a valuable
resource for high-content screening of potential neuroprotective
or disease-modifying approaches.
Concluding Remarks
In conclusion, compelling evidence supports the notion that
AβOs are the proximal toxins that cause synapse failure and,
ultimately, memory loss in AD. Although questions remain
to be answered, e.g., concerning the identity (or identities)
of the neuronal receptor(s) to which oligomers bind and the
size/nature of the most synaptotoxic species, we now know a
great deal about aberrant signaling pathways and mechanisms
by which oligomers affect neuronal physiology and, specifically,
synapse function (Figure 1). Recent efforts have also aimed to
develop experimental models that more closely recapitulate the
human disease and allow for detailed testing of novel potentially
disease-modifying therapeutics. Together, such developments
offer reasons for optimism in the quest towards development of
effective approaches to prevent or rescue synapse damage in AD.
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